NCT00463879View on ClinicalTrials.gov

Galantamine for Cognitive Deficits in Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

September 30, 2007

Conditions
Schizophrenia
Interventions
DRUG

Galantamine

Trial Locations (1)

06519

Connecticut Mental Health Center, Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

lead

Yale University

OTHER

NCT00463879 - Galantamine for Cognitive Deficits in Schizophrenia | Biotech Hunter | Biotech Hunter